Actuate Therapeutics, Inc. (ACTU – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on the stock and has a $20.00 price target.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Swayampakula Ramakanth’s rating is based on the promising results from Actuate Therapeutics’ ongoing clinical trials. The company’s lead drug, elraglusib, in combination with GnP, has shown significant improvements in survival rates for patients with metastatic pancreatic cancer. The topline data presented at the ASCO meeting demonstrated that the combination therapy met its co-primary endpoints, with a notable increase in the 1-year overall survival rate compared to GnP alone.
Furthermore, subgroup analyses provided additional support for the efficacy of elraglusib, showing a statistically significant improvement in median overall survival and a reduction in the risk of death. The drug’s safety profile remains favorable, with no elraglusib-related deaths reported, and the most common adverse event being a minor visual disturbance. These strong clinical outcomes, despite the inclusion of sicker-than-expected patients, suggest that elraglusib could become a preferred treatment option, justifying the Buy rating.